A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Key facts
- Who runs it
- Daré Bioscience, Inc.
- Where
- Columbus, Grand Island, Houston, Layton, Little Rock, Mobile, Pearland, Phoenix, Saint Paul, Seattle, and Tucson, United StatesSee the 11 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 118 people, planned
- Started
- 17 Jul 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lopinavir / ritonavir
- Record updated
- 6 November 2026
Who can take part
- Age
- 22 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Provision of written informed consent prior to any study-specific procedures
- Premenopausal women aged 22-50 years inclusive at the time of screening visit
- Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 months (history of persistent hrHPV infection for at least 12 months), based on review of participant's medical records. The visit 1 screening genital hrHPV test may be the second positive test
- Generally, in good health with no clinically significant disease as determined by the Investigator
- Regular menstrual cycle with an approximate 28-day cycle OR women who are amenorrheic due to effective contraception (such as levonorgestrel intrauterine system, or continuous oral contraception)
- Agree to refrain from vaginal douching, insertion of intravaginal devices (e.g., tampons, menstrual cups), and use of condoms for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug
- Agree to abstain from all vaginal and oral intercourse for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug
- Women at risk of pregnancy must use a highly effective form of birth control (confirmed by the Investigator) for the entire duration of the study. Rhythm methods and consistent use of condoms will not be considered as highly effective methods of birth control. Highly effective forms of birth control include:; Heterosexual abstinence; Vasectomized male partner (provided that the male partner is the sole sexual partner of the female participant with childbearing potential and that the vasectomized partner has received medical assessment of the surgical success); Oral or transdermal combined ethinyl estradiol/progestin hormonal contraception associated with inhibition of ovulation; Oral, injectable or implantable progestogen-only hormone contraception associated with inhibition of ovulation (e.g., Depo-Provera™, Nexplanon, Slynd); Any effective copper intrauterine device/levonorgestrel intrauterine system; Female sterilization by tubal occlusion or bilateral salpingectomy; Supracervical hysterectomy
- Ability and willingness to attend the necessary visits to the study center
- Ability to comprehend all study related documentation, including written informed consent form, and complete all study-related tasks including daily diary
- Be willing and able to adhere to the prohibitions and restrictions specified in the protocol
Who cannot take part
- Cytological abnormality of the uterine cervix defined as LSIL or mild cervical intraepithelial neoplasia (CIN1), or HSIL or moderate (CIN 2) or severe (CIN 3) histology, as proven by cytology or colposcopic biopsy collected within the 12 months prior to screening or cytology at screening
- Currently taking systemic immunosuppressants, biologics, intra-vaginal preparations, or any prescription that in the opinion of the Investigator could be a potential safety issue or interfere with the interpretation of the results
- Previous exposure to lopinavir/ritonavir (within 3 months prior to screening), contraindication to the use of lopinavir/ritonavir or known allergy, hypersensitivity, or intolerance to any component of lopinavir/ritonavir excipients
- Recent history (within 3 months prior to screening) of Stevens-Johnson syndrome, erythema multiforme, urticaria, or angioedema
- Receipt of any investigational product within 30 days or 5 half-lives prior to dosing
- Any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study
- Active pelvic infection (positive for gonorrhea or chlamydial infection, positive test and symptoms for bacterial vaginosis, candida vaginitis or trichomonal vaginitis). Participants with positive results can be treated and re-tested once during screening
- Positive result for hepatitis B, hepatitis C antibody or human immunodeficiency virus
- Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the Investigator, may put the participant at risk because of her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study
- Pregnant, breastfeeding, or lactating women (WOCBP must have a negative urine pregnancy test at screening and at the start of treatment [i.e., Day 1])
- Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular, the study restrictions and risks involved)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 22 and 50 years old?
This trial is currently available in United States.
- AMR Clinical ColumbusColumbus, United StatesContact: Kayla WintersTaking people
- Velocity Clinical Research - Grand IslandGrand Island, United StatesContact: Nadia McCann, Sub-ITaking people
- Innovative Medical Research of TexasHouston, United StatesContact: Karyn Cumberbatch, PI, MDTaking people
- Alpine Research Organization, Inc.Layton, United StatesContact: Chelsie HardingTaking people
- Applied Research Center of Arkansas/Cornerstone Clinic for WomenLittle Rock, United StatesContact: Allie BarkerTaking people
- Velocity Clinical Research, MobileMobile, United StatesContact: Recruitment OfficeTaking people
- Activian Clinical ResearchPearland, United StatesContact: Lori Hoskins, Clinical Trials Associate DirectorTaking people
- Precision Clinical Trials-ArizonaPhoenix, United StatesContact: Ali HamiehTaking people
- Planned Parenthood North Central StatesSaint Paul, United StatesContact: Christy Boraas, MDTaking people
- Seattle Clinical Research CenterSeattle, United StatesContact: Recruitment DepartmentTaking people
- Del Sol Research Management, LLCTucson, United StatesContact: Wendy Hotz, PresidentTaking people
About the trial
What the trial wants to find out
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
Read full original descriptionShow less
The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.
The 6 groups in the trial
- DARE-HPV-LD 14 dayExisting treatment, for comparison
14 day administration of DARE-HPV low dose
Treatment: Lopinavir / ritonavir
- DARE-HPV-LD 21 dayExisting treatment, for comparison
21 day administration of DARE-HPV low dose
Treatment: Lopinavir / ritonavir
- DARE-HPV-HD 14 dayExisting treatment, for comparison
14 day administration of DARE-HPV high dose
Treatment: Lopinavir / ritonavir
- DARE-HPV-HD 21 dayExisting treatment, for comparison
21 day administration of DARE-HPV high dose
Treatment: Lopinavir / ritonavir
- Placebo 14 dayNo study treatment, for comparison
14 day administration of placebo product
- Placebo 21 dayNo study treatment, for comparison
21 day administration of placebo product
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection
- Criteria questions
- Built from NCT07601074, who can take part
- Record updated
- 6 November 2026